Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ATN
110512 (ATN.TO)
C$0.00
C$0.05
C$0.12
N/AN/A7,519 shsN/A
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
$70.95
+0.8%
$67.32
$40.00
$99.50
$2.71B0.93585,588 shs185,907 shs
Don't wait for the SpaceX IPO Cover

The space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
+3.46%+0.85%+5.14%+16.59%+48.42%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ATN
110512 (ATN.TO)
C$0.00
C$0.05
C$0.12
N/AN/A7,519 shsN/A
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
$70.95
+0.8%
$67.32
$40.00
$99.50
$2.71B0.93585,588 shs185,907 shs
Don't wait for the SpaceX IPO Cover

The space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
+3.46%+0.85%+5.14%+16.59%+48.42%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ATN
110512 (ATN.TO)
0.00
N/AN/AN/A
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
2.75
Moderate Buy$105.3048.42% Upside

Current Analyst Ratings Breakdown

Latest PYX, IRON, ALBA, and ATN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Boost Price TargetOverweight$75.00 ➝ $80.00
4/20/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Reiterated RatingSell (D-)
(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ATN
110512 (ATN.TO)
N/AN/AN/AN/AN/AN/A
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
N/AN/AN/AN/A$19.52 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ATN
110512 (ATN.TO)
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-$212.18M-$6.62N/AN/AN/AN/A-36.94%-33.88%8/6/2026 (Estimated)

Latest PYX, IRON, ALBA, and ATN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2026Q1 2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-$1.6227-$1.65-$0.0273-$1.65$0.44 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ATN
110512 (ATN.TO)
N/AN/AN/AN/AN/A
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ATN
110512 (ATN.TO)
N/AN/AN/A
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
0.04
24.00
24.00

Institutional Ownership

CompanyInstitutional Ownership
ATN
110512 (ATN.TO)
N/A
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
83.70%

Insider Ownership

CompanyInsider Ownership
ATN
110512 (ATN.TO)
N/A
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
3.76%
CompanyEmployeesShares OutstandingFree FloatOptionable
ATN
110512 (ATN.TO)
N/AN/AN/ANot Optionable
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
3038.16 million36.73 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines

110512 (ATN.TO) TSE:ATN

Atna Resources Ltd. is engaged in all phases of the mining business, including exploration, preparation of Pre-Feasibility and Feasibility studies, permitting, construction and development, operation and final closure of mining properties. The Company owns or controls various properties with gold resources. The Company's production property includes Briggs Mine California and Pinson Mine Property, Nevada. The Company's development properties include Mag Pit at Pinson; Columbia Project, Montana and Briggs Satellite Projects, California. Its exploration properties include Sand Creek Uranium Joint Arrangement, Wyoming; Blue Bird Prospect, Montana and Canadian Properties, Yukon and British Columbia. Its Closure Property is Kendall, Montana. The Briggs mine is located on approximately 156 unpatented claims, including approximately 15 mill site claims, covering over 2,890 acres. The Company's Pinson Mine Property is located in Humboldt County, Nevada, over 30 miles east of Winnemucca.

Disc Medicine stock logo

Disc Medicine NASDAQ:IRON

$70.94 +0.60 (+0.85%)
As of 01:03 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.